Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes.
D000818:Animals; D002986:Clinical Trials as Topic; D004361:Drug Tolerance; D006801:Humans; D007116:Immunization, Passive; D007167:Immunotherapy / Q000379:methods*; D007376:Interleukin-2 / Q000008:administration & dosage / Q000276:immunology*; D007694:Killer Cells, Natural / Q000276:immunology; D008213:Lymphocyte Activation; D008214:Lymphocytes / Q000276:immunology*; D008222:Lymphokines / Q000276:immunology; D051379:Mice; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D009374:Neoplasms, Experimental / Q000276:immunology / Q000628:therapy; D051381:Rats
D007376:Interleukin-2; D008222:Lymphokines